Premium
Effect of intravenous metoprolol on reversible obstructive airways disease
Author(s) -
Abraham Thomas A,
Hasan Faysal M,
Fenster Paul E,
Marcus Frank I
Publication year - 1981
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1981.81
Subject(s) - metoprolol , copd , medicine , pulmonary disease , adverse effect , clinical pharmacology , anesthesia , cardiology , pharmacology
We gave increasing doses of metoprolol intravenously to seven subjects with stable chronic obstructive pulmonary disease (COPD) who were also receiving their usual bronchodilators. Six of the seven tolerated up to 0.2 mg/kg metoprolol without adverse effects, although there were declines in forced expiratory volume in 1 sec (FEV 1 ). At 0.15 mg/kg mean FEV 1 fell 12% (p < 0.025), and at 0.2 mg/kg mean decline in FEV 1 was 15% (p < 0.01). These findings suggest that 0.2 mg/kg metoprolol may be given intravenously to most patients with COPD in addition to previously administered bronchodilators without precipitating clinically significant adverse effects. Any side effects that develop can be reversed by beta agonists. Clinical Pharmacology and Therapeutics (1981) 29, 582–587; doi: 10.1038/clpt.1981.81